Vatiquinone

Martinelli D, et al. Molecular Genetics and Metabolism, 2012, 107(3), 83-388.

A phase 2A open-label clinical trial evaluated Vatiquinone (EPI-743), a novel para-benzoquinone, in children with genetically confirmed Leigh syndrome, a fatal mitochondrial disorder. Ten patients aged 1-13 years, representing seven different genetic mutations, received EPI-743 orally three times daily for six months. Experimental assessment focused on neuromuscular and quality-of-life endpoints compared with the disease's natural progression. Clinical efficacy was measured using validated tools including the Newcastle Pediatric Mitochondrial Disease Scale, the Gross Motor Function Measure, and the PedsQL Neuromuscular Module. Across all patients, statistically significant improvements (p < 0.05) were documented, alongside one-class improvement in the Movement Disorder-Childhood Rating Scale. Importantly, no serious drug-related adverse events occurred. These findings demonstrate that EPI-743 effectively reversed disease progression, providing compelling evidence for its experimental therapeutic application in mitochondrial neurodegeneration.

Kouga T, et al. Brain and Development, 2018, 40(2), 145-149.

A Japanese case of Leigh syndrome caused by a mitochondrial ND3 gene mutation (T10158C) highlighted the therapeutic potential of Vatiquinone (EPI-743), a para-benzoquinone analog targeting oxidative stress. At 8 months, conventional succinate supplementation failed to restore respiratory chain activity, with worsening neurological decline. EPI-743 was subsequently administered, exploiting its capacity to modulate redox homeostasis and support electron transport chain efficiency. Clinical monitoring demonstrated marked improvements in ocular movement, extremity motor control, and gastrointestinal function. Despite progressive brain atrophy, the patient survived to 5 years with preserved respiratory-free intervals, suggesting Vatiquinone may significantly alter the disease trajectory in mitochondrial dysfunction.

Blankenberg FG, et al. Molecular Genetics and Metabolism, 2012, 107(4), 690-699.

In a clinical investigation, 22 patients with mitochondrial disorders-including Leigh syndrome, MELAS, and polymerase γ deficiency-were treated with oral Vatiquinone (EPI-743), a para-benzoquinone-based redox modulator. Cerebral oxidative status was assessed using Tc99m-HMPAO SPECT, a radiotracer sensitive to cerebral blood flow and glutathione/protein thiol levels. Baseline and 3-month follow-up scans were analyzed via NeuroGam™ software, correlating regional tracer uptake with clinical response measured by the Newcastle Paediatric or Adult Mitochondrial Disease Scale. Cerebellar HMPAO uptake changes demonstrated a significant linear correlation with clinical improvement (r = 0.623, p = 0.00161), while MELAS patients exhibited whole-brain uptake correlation (r = 0.917, p = 0.028). These findings highlight Tc99m-HMPAO SPECT as an experimental imaging tool for evaluating the in vivo redox-modulating effects of Vatiquinone (EPI-743).